



Société Anonyme à Conseil d'Administration
au capital de 21 610 998,20 euros
Siège social: 49 boulevard du Général Martial Valin, 75015 Paris
RCS 410 910 095 Paris

Press Release

Temporary suspension of trading effective 17 June 2025

Paris (France), 24 June 2025

Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) announces the temporary suspension of trading on its shares by Euronext since 17 June 2025, following the postponement of the publication of its annual financial report for the financial year ended December 31, 2024.

Valerio Therapeutics reminds its shareholders that the publication of the 2024 annual financial report has been postponed due to significant difficulties in accessing the accounting records of its US subsidiary, Valerio Therapeutics Inc. Valerio Therapeutics is currently finalising its financial statements. The report will then be published once the financial statements have been certified by the statutory auditors.

Trading on Valerio Therapeutics shares on Euronext Growth in Paris is expected to resume after the publication of the report. The Company will inform the market as soon as possible of the new publication date for the 2024 annual financial report, the final date of its General Meeting, and the effective date of the resumption of trading.

For more information, visit www.valeriotx.com.

CONTACTS

Valerio Therapeutics

Investor Relations:

ir@valeriotx.com | +33 (0) 1 70 38 33 99
